Terms: = Head and neck cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
16 results:
1. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
2. Oncogenic role of MiR-130a in oral squamous cell carcinoma.
Mallela K; Shivananda S; Gopinath KS; Kumar A
Sci Rep; 2021 Apr; 11(1):7787. PubMed ID: 33833339
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of mtor expression in HPV positive and negative head and neck cancers treated by chemoradiation.
Wilson TG; Hanna A; Recknagel J; Pruetz BL; Baschnagel AM; Wilson GD
Head Neck; 2020 Feb; 42(2):153-162. PubMed ID: 31657099
[TBL] [Abstract] [Full Text] [Related]
4. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract] [Full Text] [Related]
5. The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
Urano M; Hirai H; Tada Y; Kawakita D; Shimura T; Tsukahara K; Kano S; Ozawa H; Okami K; Sato Y; Fushimi C; Shimizu A; Takase S; Okada T; Sato H; Imanishi Y; Otsuka K; Watanabe Y; Sakai A; Ebisumoto K; Togashi T; Ueki Y; Ota H; Sato Y; Saigusa N; Nakaguro M; Hanazawa T; Nagao T
Histopathology; 2018 Dec; 73(6):943-952. PubMed ID: 29993139
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of mtor/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.
Dai D; Chen H; Tang J; Tang Y
Biochem Biophys Res Commun; 2017 Jan; 482(4):1259-1264. PubMed ID: 27932243
[TBL] [Abstract] [Full Text] [Related]
9. Impact of PI3K/AKT/mtor pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
García-Carracedo D; Villaronga MÁ; Álvarez-Teijeiro S; Hermida-Prado F; Santamaría I; Allonca E; Suárez-Fernández L; Gonzalez MV; Balbín M; Astudillo A; Martínez-Camblor P; Su GH; Rodrigo JP; García-Pedrero JM
Oncotarget; 2016 May; 7(20):29780-93. PubMed ID: 27119232
[TBL] [Abstract] [Full Text] [Related]
10. Targeting the PI3K/AKT/mtor pathway in squamous cell carcinoma of the head and neck.
Simpson DR; Mell LK; Cohen EE
Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma.
Freudlsperger C; Horn D; Weißfuß S; Weichert W; Weber KJ; Saure D; Sharma S; Dyckhoff G; Grabe N; Plinkert P; Hoffmann J; Freier K; Hess J
Int J Cancer; 2015 Jun; 136(12):2775-85. PubMed ID: 25388642
[TBL] [Abstract] [Full Text] [Related]
12. PI3K/PTEN/AKT/mtor polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
[TBL] [Abstract] [Full Text] [Related]
13. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract] [Full Text] [Related]
15. Decreased lymphangiogenesis and lymph node metastasis by mtor inhibition in head and neck cancer.
Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
[TBL] [Abstract] [Full Text] [Related]
16. Phosphorylated mtor expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima R; Sato N; Imamura Y; Hiyoshi Y; Nagai Y; Hayashi N; Iyama K; Baba H
Ann Surg Oncol; 2010 Sep; 17(9):2486-93. PubMed ID: 20339946
[TBL] [Abstract] [Full Text] [Related]
